Topical Betaxolol for the Prevention of Retinopathy of Prematurity

Smith-Kettlewell Eye Research Institute23 enrolled

Overview

We hypothesize that topical betaxolol will reduce the development of severe retinopathy of prematurity.

The drug is administered twice a day between 32 and 35 weeks gestational age, at a t ime when ROP is most likely to arise.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

TRIPLE

Enrollment

given topically

Sex: ALLMin age: 32 WeeksMax age: 32 Weeks

Medical Language ↔ Plain English

Inclusion Criteria: * \<1251 grms birth weight Exclusion Criteria: * ocular defect

development of apnea and or bradycardia

babies were monitored and HR/RR monitored and recorded by masked observers, periodically

Time frame: 3 weeks

development of ROP requiring treatment

Type I ROP was used as a secondary outcome measure

Time frame: 7 weeks

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.